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Purpose: To investigate whether the A69S variant of the age-related maculopathy susceptibility 2 gene (ARMS2) has a
different hereditary contribution in neovascular age-related macular degeneration (AMD) and polypoidal choroidal
vasculopathy (PCV).
Methods:  We  initially  conducted  a  comparative  genetic  analysis  of  neovascular  AMD  and  PCV,  genotyping  the
ARMS2 A69S variant in 181 subjects with neovascular AMD, 198 subjects with PCV, and 203 controls in a Japanese
population. Genotyping was conducted using TaqMan technology. Results were then integrated into a meta-analysis of
previous studies representing an assessment of the association between the ARMS2 A69S variant and neovascular AMD
and/or PCV, comprising a total of 3,828 subjects of Asian descent. The Q-statistic test was used to assess between-study
heterogeneity. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a fixed effects model.
Results: The genetic effect of the A69S variant was stronger in neovascular AMD (allelic summary OR=3.09 [95% CI,
2.71–3.51], fixed effects p<0.001) than in PCV (allelic summary OR=2.13 [95% CI, 1.91–2.38], fixed effects p<0.001).
The pooled risk allele frequency was significantly higher in neovascular AMD (64.7%) than in PCV (55.6%). The
population attributable risks for the variant allele were estimated to be 43.9% (95% CI, 39.0%–48.4%) and 29.7% (95%
CI,  25.4%–34.0%)  for  neovascular  AMD  and  PCV,  respectively.  No  significant  between-study  heterogeneity  was
observed in any statistical analysis in this meta-analysis.
Conclusions: Our meta-analysis provides substantial evidence that the ARMS2 A69S variant confers a significantly higher
risk of neovascular AMD than PCV. Furthermore, there is compelling evidence that the risk attributable to the A69S
variant differs between geographic atrophy and neovascular AMD. Together with defining the molecular basis of
susceptibility, understanding the relationships between this genomic region and disease subtypes will yield important
insights, elucidating the biologic architecture of this phenotypically heterogeneous disorder.
Age-related  macular  degeneration  (AMD),  a  leading
cause of irreversible blindness among older individuals in
developed countries, is a common multifactorial disease with
heterogeneous clinical manifestations [1]. An early hallmark
lesion of AMD is large drusen and pigmentary abnormalities
in the retinal pigment epithelium of the macula. The advanced
form of the disease is classified into two main groups: “dry”
and “wet” types; the former is characterized by geographic
atrophy  and  the  latter  by  the  development  of  choroidal
neovascularization (CNV) in the central macula (neovascular
AMD). AMD has divergent clinical features between racial
groups, and the ratio of neovascular AMD to dry AMD is
higher in Asian than in European populations [2-5].
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Remarkable  progress  has  recently  been  made  in
understanding  the  genetic  basis  of  AMD.  Several  AMD
susceptibility  loci  have  been  established  with  convincing
statistical evidence, including the complement factor H gene
on chromosome 1q32 [6-8], two tightly linked genes on 10q26
(age-related maculopathy susceptibility 2 [ARMS2] [9] and
high-temperature requirement factor H [HTRA1]) [10,11], the
complement  component  3  gene  on  19p13  [12],  two
neighboring  genes  on  6p21  (complement  factor  B  and
complement component 2) [13], the complement factor I gene
on 4q25 [14], the hepatic lipase gene on 15q22 [15,16], the
cholesterylester transfer protein gene on 16q21 [15,16], and
the tissue inhibitor of the metalloproteinase 3 gene on 22q12
[15,16]. Recent additions to the growing list of potential AMD
risk loci include 6q21–q22.3 that encompass two genes—the
collagen, type X, alpha 1 gene and the fyn-related kinase gene
—and 6p12 harboring the vascular endothelial growth factor
A gene, which were identified through a recent large-scale
meta-analysis of genome-wide association study for advanced
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3574AMD [17]. The meta-analysis showed that the missense allele
encoding A69S (rs10490924) in ARMS2 confers the strongest
disease risk, among others [17].
Polypoidal choroidal vasculopathy (PCV), characterized
by inner choroidal vascular networks ending in polypoidal
lesions [18], is now clinically classified as a specific type of
AMD  [19].  PCV  is  particularly  prevalent  in  Asian
populations,  accounting  for  54.7%  of  patients  with  the
neovascular form of AMD in the Japanese population [20] and
24.5% in the Chinese population [21], but only 8% to 13% in
Caucasians  [22].  PCV  shares  many  similarities  with
neovascular AMD, including demography [20], pathology
[23,24],  and  manifestation  [20];  however,  important
differences have been noted in histopathology [25], clinical
behavior  [22],  and  response  to  therapy  [18,26].  These
similarities  and  differences  have  been  a  subject  of  much
interest  and  debate  regarding  whether  the  vascular
abnormality  in  PCV  represents  neovascularization  or  a
phenotype distinct from CNV [23-25,27].
We have previously shown that the ARMS2 A69S variant
is strongly associated with neovascular AMD and PCV, with
a  stronger  association  in  neovascular  AMD  than  in  PCV
[28]; however, the difference was not statistically significant,
probably owing to a limitation in statistical power. Subsequent
A69S association studies have consistently reported a trend
toward stronger evidence for association in neovascular AMD
than in PCV [29-31]. Interestingly, a significant difference in
genetic  susceptibility  between  geographic  atrophy  and
neovascular AMD has been repeatedly observed at this locus
[17,32].  Sub-phenotype  associations  are  currently  being
actively  researched  in  complex  diseases,  such  as
inflammatory bowel disease [33], rheumatoid arthritis [34],
and  various  cancers  [35-37].  Genotype–phenotype
correlations between risk alleles and disease subtypes may
provide an insight into the underlying etiologic pathways of
complex diseases.
To  date,  some  meta-analyses  have  been  published
regarding the association between AMD and the  ARMS2/
HTRA1 region [38-40], but none of these studies focused on
PCV. Here we conducted a comparative genetic analysis of
neovascular AMD and PCV in our original sample set of
Japanese ancestry, genotyping the ARMS2 A69S variant in
181 subjects with neovascular AMD, 198 subjects with PCV,
and 203 controls. Results were then integrated into a meta-
analysis of previous studies representing an assessment of the
association  between  the  ARMS2  A69S  variant  and
neovascular AMD and/or PCV, comprising a total of 3,828
subjects  of  Asian  descent,  to  more  reliably  compare  the
genetic effect of ARMS2 A69S between neovascular AMD
and PCV.
METHODS
New data set: Study participants: The study protocol was
approved  by  the  Institutional  Review  Board  at  Kobe
University Graduate School of Medicine and performed in
accordance  with  the  Declaration  of  Helsinki.  Written
informed  consent  was  obtained  from  all  subjects  before
participation in this study. All cases and controls included in
our original sample set were Japanese individuals recruited
from the Department of Ophthalmology at Kobe University
Hospital in Kobe, Japan. This cohort is an extension of one
previously published for an association with the ARMS2 A69S
variant [28]. A portion of the subjects in the present study had
participated in our previous studies in which phenotyping
criteria  were  fully  described  [28,41,42].  In  brief,  all  our
subjects  with  neovascular  AMD  and  PCV  underwent  a
comprehensive  ophthalmic  examination  including
indocyanine green angiography, and were defined as having
angiographically well defined lesions of CNV or PCV. The
controls were not related to the cases and were defined as
individuals without macular degeneration and changes such
as drusen or pigment abnormalities, and were thus categorized
as having clinical age-related maculopathy staging system
stage 1 [43]. The demographic details of the study subjects are
listed in Table 1.
Genotyping: Genomic DNA was extracted from peripheral
blood  using  a  standard  methodology.  Genotyping  was
performed using a pre-developed TaqMan SNP Genotyping
Assay  (Assay  ID:  C_29934973_20;  Applied  Biosystems,
Foster City, CA) on a StepOnePlus™ Real-Time PCR System
(Applied Biosystems) in accordance with the manufacturer’s
recommendations.
Statistical analysis: Allelic associations were evaluated for
the  ARMS2  A69S  variant  with  chi-square  tests  on  2  ×  2
contingency  tables  using  the  software  package  PLINK
v1.07.  Deviations  from  the  Hardy–Weinberg  equilibrium
TABLE 1. CHARACTERISTICS OF THE STUDY POPULATION
Groups Neovascular AMD PCV Control
Number of subjects 181 198 203
Gender (male/female) 139/42 157/41 120/83
Mean age ± SD (years) 75±7.4 73±7.3 72±6.0
Age range (years) 55–94 54–93 56–95
          Abbreviations: AMD, age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; SD, standard deviation.
Molecular Vision 2011; 17:3574-3582 <http://www.molvis.org/molvis/v17/a384> © 2011 Molecular Vision
3575(HWE) were tested using the exact test [44] implemented in
PLINK.  The  odds  ratio  (OR)  and  corresponding  95%
confidence interval (CI) were calculated relative to the major
allele.  Genotype-specific  ORs  were  estimated  for  the
heterozygous  (GT)  and  risk  homozygous  (TT)  genotypes,
with the common homozygous (GG) genotype the baseline
category with unconditional logistic regression using the JMP
software (version 6.0.3; SAS Institute, Cary, NC). To test for
heterogeneity between ORs for neovascular AMD and PCV,
we conducted a logistic regression analysis of the cases (case-
only analysis) using R project, where the subtypes were used
as the outcome and the A69S genotype as the explanatory
variable [45].
Meta-analysis:  Identification  and  eligibility  of  relevant
studies: We performed a systematic PubMed literature search
(up to May 2011) using the following search terms in different
combinations: “HtrA serine peptidase 1” or “HTRA1,” “age-
related  maculopathy  susceptibility  2,”  “ARMS2,”  or
“LOC387715,” and “age-related macular degeneration” or
“polypoidal choroidal vasculopathy.” The literature search
was performed in duplicate by two authors (S.Y. and N.K.).
Studies included in the meta-analysis had to fulfill the
following  criteria:  (1)  The  study  must  be  unrelated  case-
control or population-based representing an assessment of the
association  between  the  ARMS2  A69S  variant  and
neovascular AMD and/or PCV in East Asian populations. (2)
The study must distinguish PCV from the neovascular form
of AMD based on findings of indocyanine green angiography,
and must look at PCV and/or neovascular AMD (CNV) as
specific outcomes. (3) The study must present available data
on allele and genotype distributions for cases and controls. (4)
The study must be written in English and published in peer-
reviewed journals. For duplicate publications, the largest data
set was chosen for meta-analysis.
Data extraction: The following variables were extracted from
each  study:  the  name  of  the  first  author,  the  year  of
publication, ethnicity, and allele and genotype distributions in
cases and controls.
Statistical analyses: For each study, deviations from the HWE
in controls were tested using the exact test [44]. Pooled allele
and genotype frequencies of the A69S variant were estimated
with  the  fixed  effects  model  [46]  if  heterogeneity  among
studies was absent, or with the random effects model [47] if
heterogeneity was present. We estimated summary ORs and
95%  CIs  according  to  the  Mantel–Haenszel  fixed  effects
model [46] if heterogeneity among studies was absent or the
DerSimonian–Laird random effects model [47] if there was
evidence  of  between-study  heterogeneity.  The  population
attribute risk was calculated to demonstrate the number of
cases in the total population that could be attributed to the risk
genotype, as described previously [48].
Between-study heterogeneity was assessed using the Q-
statistic test and I2 statistic [49,50]. A p value of <0.1 was
considered statistically significant for the Q-statistic test. I2
ranges between 0% and 100% (where a value of 0% represents
no  heterogeneity),  and  larger  values  represent  increasing
heterogeneity.
All  meta-analyses  were  conducted  using  the  Stata
software (version 11.0; Stata Corporation, College Station,
TX).  All  tests  were  two  tailed.  A  p  value  of  <0.05  was
considered  statistically  significant  except  for  the  test  of
between-study heterogeneity.
RESULTS
Comparative genetic analysis in our original sample set: We
initially  conducted  a  comparative  genetic  analysis  of
neovascular AMD and PCV, genotyping the ARMS2 A69S
variant (rs10490924) in our original sample set. Genotype
distributions for this variant are given in Table 2, along with
those  of  other  studies  included  in  the  subsequent  meta-
analysis. No departure from the HWE was observed at this
variant  among  the  controls  (p=0.88).  As  expected,  the
ARMS2 A69S variant showed strong evidence of association
with neovascular AMD and PCV. ORs for the risk allele T
were 2.82 (95% CI, 2.10–3.78, p=2.4×10−12) and 2.39 (95%
CI, 1.80–3.17, p=1.3×10−9) for neovascular AMD and PCV,
respectively. For heterozygous and homozygous carriers of
the risk allele, the genotype-specific OR was 2.62 (95% CI,
1.55–4.52) and 7.49 (95% CI, 4.11–14.07) for neovascular
AMD and 1.56 (95% CI, 0.97–2.53) and 5.02 (95% CI, 2.89–
8.90) for PCV, respectively. Similar to previous findings of
ARMS2 A69S association studies [29-31], the variant showed
a trend toward stronger effect in neovascular AMD than in
PCV. However, a case-only heterogeneity test with logistic
regression  analysis  showed  a  nonsignificant  value  in  our
original sample set (heterogeneity p=0.31), possibly reflecting
inadequate statistical power in this single study. Our own data
were then combined with those from previously published
studies in the subsequent meta-analysis.
Meta-analysis: Eligibility of studies: Our search identified
five studies that met our inclusion criteria [29-31,51,52]. Data
from these five studies and our original study were combined
for the meta-analysis. Table 2 lists the studies included in the
meta-analysis.  The  combined  sample  size  for  this  meta-
analysis was 3,828.
Allele and genotype frequency: None of the five previously
published studies demonstrated significant deviation from the
HWE  among  controls  (Table  2).  To  estimate  the  pooled
frequency of the A69S variant in Asian populations, we used
allele data from controls. The pooled frequency for the risk
allele T was 37.4% (95% CI, 35.9–38.8), and individuals
carrying  at  least  one  copy  of  the  risk  allele  (GT  +  TT)
accounted  for  60.8%  (95%  CI,  58.7–62.9)  of  the  control
populations.  No  evidence  of  heterogeneity  in  these
frequencies  was  observed  among  controls  across  the  six
studies (allele frequency, Q=8.50, 5 degrees of freedom [d.f.],
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d.f., p=0.11, I2=44.5%).
Quantitative synthesis: We conducted a meta-analysis based
on  an  allele  contrast  model.  The  A69S  variant  showed  a
significant summary OR of 3.09 ([95% CI, 2.71–3.51], fixed
effects p<0.001; Figure 1) for neovascular AMD and 2.13
([95% CI, 1.91–2.38], fixed effects p<0.001; Figure 2) for
PCV. The Q-statistic test showed no significant between-
study heterogeneity in association tests for neovascular AMD
or  PCV  (p>0.1;  Figure  1  and  Figure  2).  The  population
attribute risks for the risk allele were 43.9% (95% CI, 39.0%–
48.4%) and 29.7% (95% CI, 25.4%–34.0%) for neovascular
AMD and PCV, respectively. Next, we compared the allele
frequencies  of  the  variant  between  the  two  subtypes,
combining data from four studies that included neovascular
AMD and PCV subtypes in the case groups (Table 2). The
pooled  risk  allele  frequency  was  significantly  higher  in
neovascular  AMD  than  in  PCV  (64.7%  versus  55.6%;
p<0.001), without heterogeneity across studies (Q=5.38, 3
days.f.,  p=0.15,  I2=44.3%).  This  result,  coupled  with  the
finding  that  the  95%  CIs  for  allelic  summary  ORs  for
neovascular  AMD  did  not  overlap  with  those  for  PCV,
indicates that the genetic effect of the ARMS2 A69S variant
is significantly stronger in neovascular AMD than in PCV.
DISCUSSION
Several studies have reported that the ARMS2 A69S variant is
strongly associated with neovascular AMD and PCV, with a
stronger  association  in  neovascular  AMD  than  in  PCV
[29-31]. However, the differences between the two were not
statistically significant in most studies, probably owing to a
limitation  in  the  statistical  power.  Our  meta-analysis  has
revealed that the ARMS2 A69S variant confers a significantly
greater risk of neovascular AMD than of PCV. The pooled
TABLE 2. ALLELE AND GENOTYPE DISTRIBUTIONS OF THE ARMS2 A69S VARIANT OF CASE-CONTROL STUDIES CONTRIBUTING TO THE META-ANALYSIS
      Genotype (GG/GT/TT) Risk allele frequency  
Study Year Ethnicity Neovascular AMD PCV Control          Neovascular AMD PCV Control PHWE*
[51] 2008 Japanese NA 15/49/45 39/32/14 NA 0.64 0.35 0.10
[52] 2008 Chinese NA 17/30/25 33/48/12 NA 0.56 0.39 0.51
[29] 2009 Japanese 18/30/52 18/50/32 85/84/20 0.67 0.57 0.33 1.0
[30] 2010 Japanese 67/155/183 122/216/171 502/638/196 0.64 0.55 0.39 0.82
[31] 2011 Japanese 6/20/24 22/20/18 64/58/16 0.68 0.47 0.33 0.70
This
study
2011 Japanese 26/81/74 42/77/79 79/94/30 0.63 0.59 0.38 0.88
         Abbreviations: ARMS2, age-related maculopathy susceptibility 2; AMD, age-related macular degeneration; PCV, polypoidal
         choroidal vasculopathy; HWE, Hardy–Weinberg equilibrium; NA, not available. *p values generated by the exact test for Hardy–
         Weinberg equilibrium.
Figure 1. Forest plot showing the association between ARMS2 A69S and neovascular age-related macular degeneration. Odds ratios (black
squares) and 95% confidence intervals (bars) are given for each study. Also shown are the unshaded diamonds of the summary odds ratio
based on the Mantel–Haenszel fixed effects model.
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3577risk allele frequency was significantly higher in neovascular
AMD  (64.7%)  compared  with  PCV  (55.6%).  The  meta-
analysis estimated the attributable risks for the variant allele
were  43.9%  and  29.7%  for  neovascular  AMD  and  PCV,
respectively. In the control populations, the pooled frequency
for the risk allele T of the A69S variant was estimated to be
37.4%, and individuals carrying at least one copy of the risk
allele accounted for 60.8%, indicating its population-wide
epidemiological consequence in Asian populations owing to
the high frequency of the risk allele. No significant between-
study heterogeneity was observed in any statistical analysis in
this meta-analysis of Asian populations.
There  is  increasing  evidence  that  ethnicity  influences
disease via genetic background [53]. Risk allele frequencies
of  A69S  diverge  greatly  between  European  and  Asian
populations from the HapMap sample, with almost 40% risk
allele frequencies in Asian populations compared to 20% in
individuals  of  European  descent.  The  distributions  of  the
neovascular  subtype  of  AMD  differ  markedly  between
European and Asian populations, and parallel the risk allele
frequencies of this variant, with Asians having a much higher
rate  of  the  neovascular  subtype  than  Europeans  [2-5],
suggesting  that  this  locus  may  contribute  to  ethnic
heterogeneity in the manifestation of AMD subtypes.
Currently, how the ARMS2/HTRA1 region on 10q26 is a
source of genetic risk for AMD is unclear. Much effort has
been made to localize variant(s) causally related to AMD in
this  region  and  to  understand  the  molecular  basis  of  the
susceptibility [10,11,54-58]. However, there is high linkage
disequilibrium  (LD)  across  the  ARMS2/HTRA1  region,
adding to the difficulty in identifying true causal variant(s) by
association  mapping  alone  [55].  The  association  signal  at
10q26  converges  on  a  region  of  an  extensive  LD  block
spanning ARMS2 and HTRA1 [54,55]. This LD block harbors
multiple  susceptibility  alleles  of  which  the  ARMS2  A69S
variant has been reported to show the strongest evidence for
association [54]. Two variants within this LD block that were
correlated with A69S through strong LD—SNP rs11200638
in the promoter of HTRA1 [10,11] and the insertion/deletion
polymorphism  (c.(*)372_815del443ins54)  in  the  3′-UTR
region  of  ARMS2  [55]—have  recently  been  proposed  as
causal variants based on mechanistic functional evidence, but
there is no agreement across studies [10,11,54-58]. Thus, the
molecular basis of the susceptibility remains obscure.
In  conclusion,  our  meta-analysis  has  identified  a
difference in the hereditary contribution of the ARMS2 A69S
variant between neovascular AMD and PCV. In addition, a
significant difference has been reported between geographic
atrophy  and  neovascular  AMD  with  respect  to  genetic
susceptibility at this locus [17,32]. This fact, coupled with our
findings, indicates that the risk attributable to the A69S variant
differs among AMD subtypes. Given the importance of the
ARMS2/HTRA1  region  on  10q26  in  AMD  susceptibility,
defining molecular mechanisms through which the genomic
variants  influence  disease  risk  and  understanding  the
relationships between this region and disease subtypes will
yield important insights, elucidating the biologic architecture
of this phenotypically heterogeneous disorder.
Figure 2. Forest plot showing the association between ARMS2 A69S and polypoidal choroidal vasculopathy. Odds ratios (black squares) and
95% confidence intervals (bars) are given for each study. Also shown are the unshaded diamonds of the summary odds ratio based on the
Mantel–Haenszel fixed effects model.
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